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Abstract To study the relationship between the tyrosine kinase c&c and the epidermal growth factor receptor (EGF-R), we used the breast cancer 
cell line ZR75-1, which was transfected with the EGF-R. The EGF-R transfected cell line expressed 60 times more EGF-R than a control cell line 
transfected with the empty vector. In the presence of EGF, the EGF-R over-expressing cell line grew much faster than the control cell line. Both 
cell lines expressed approximately equal amounts of c-Src. However, the cell line over-expressing the EGF-R showed a twofold enhancement of c-Src 
kinase activity after EGF stimulation. The activation of c-Src kinase by EGF was confirmed in other EGF-R expressing cell types. 
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1. Introduction 
The tyrosine kinase activity of growth factor receptors is 
critical for the signal transduction pathways required for mito- 
genesis, transformation and cell differentiation [l]. After the 
activation of growth factor receptors, a multitude of processes 
takes place, including dimerization of the receptors, auto- 
phosphorylation, and transduction of the signal to the interior 
of the cell. In the past few years, it has become increasingly clear 
that binding of the substrates to the activated growth factor 
receptors requires their SH2 (Src homology 2) domains [2]. 
Examples are given by the GTPase activating protein of ras 
[3,4], phospholipase C-y [5,6], the 85 kDa subunit of phosphat- 
idylinositol-3 kinase [7,8], she [9], GRB2 [lo], vav [11,12] and 
Src, Fyn and Yes [13]. It has been shown that the Src tyrosine 
kinase can associate with different growth factor receptors, for 
example, to the platelet-derived growth factor receptor (PDGF- 
R). The kinase activity of c-Src was elevated after PDGF stim- 
ulation of quiescent fibroblasts, coincident with transient asso- 
ciation of Src with the PDGF-R [ 131. Also, an interaction with 
the activated colony-stimulating factor-l (CSF-1) receptor has 
been shown [14]. In contrast, the involvement of the Src kinase 
in EGF receptor signaling is less clear. Recently, evidence was 
presented that Src becomes associated to the activated EGF 
receptor in breast carcinoma cell lines [15]. In the present re- 
port, we further studied the relationship between the EGF-R 
and the Src kinase using the breast cancer cell line ZR75-1, 
which was transfected with the EGF-R, or a control ZR75-1 
cell line transfected with an empty vector. We now show that 
EGF stimulation of the EGF-R over-expressing cells resulted 
in enhancement of c-Src tyrosine kinase activity. Activation of 
c-Src kinase by EGF appeared to be a general phenomenon and 
could be reproduced in other cell types. 
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2. Materials and methods 
2.1. Cell culture 
ZR75-1 human breast cancer cells, trafisfected with the EGF receptor 
(ZRll) or the empty vector (ZR9Bll), were kindly donated by E. 
Valverius and have been described elsewhere [16]. HER14 cells (NIH- 
3T3 cells transfected with wild-type EGF receptor [17]) were provided 
by J. Boonstra (Utrecht, The Netherlands); Al72 cells are non-manip- 
ulated glioblastoma cells expressing EGF receptors (own unpublished 
observation) and were obtained from the American Type Culture Col- 
lection (Rockville, MD). Cells were routinely cultured in Dulbecco’s 
modified Eagle’s medium supplemented with 10% heat-inactivated fetal 
calf serum, 2 mM L-glutamine, 100 U/ml penicillin and 100 &ml 
streptomycin, in a 5% CO* humidified atmosphere at 37°C. 
2.2. EGF stimulation 
For the stimulation of cells with EGF, either 4.6 x lo6 (for short-term 
stimulation) or 1.7 x lo6 cells (for long-term stimulation) were plated 
in culture dishes (14 cm diam.) in HEPES-buffered (pH 7.4), Phenol 
red-free RPM1 with 10% fetal calf serum. After 72 h, the medium was 
replaced with RPM1 containing 5% DCC ([I 81 dextran-treated, char- 
coal stripped calf serum). 48 h later, the cells were stimulated with EGF 
for 10 min (short-term stimulation), or for 48 h (long-term stimulation). 
Cell number after long-term stimulation was determined by Methylene 
blue staining of the cells, according to [19,20]. 
2.3. Sample preparation 
Cells were washed three times with ice-cold PBS and scraped in to 
extraction buffer containing 50 mM HEPES (pH 7.5), 1.5 mM Mg- 
acetate, 5 mM EDTA, 5 mM EGTA, 1 mM dithiothreitol, 10% glyc- 
erol, 1 mM phenylmethylsulfonyl fluoride, 0.055 TIU/ml aprotinin and 
100 PM Na,VO,. The sample was sonicated twice for 5 s (4”C), centri- 
fuged at 800 x g for 10 min (4°C) to remove whole cells and nuclei, and 
the supernatant was clarified by centrifugation at 48,000 x g for 60 min 
(4’C). The 48,000 x g supematant was used as the cytosolic fraction. 
The remaining pellet was solubilized in extraction buffer containing 1% 
Nonidet P-40. This membrane fraction was kept on ice for 1 h, during 
which it was sonicated twice for 10 s (4°C). The solubilized membrane 
fraction was obtained by clarification at 48,000 x g for 60 min (4’C). 
Protein was determined according to Bradford [21]. 
2.4. Zmmunoprecipitation 
Immunoprecipitations were performed as described previously [22]. 
Src was precipitated from cytosolic fractions (0.5 mg of protein) and 
solubilized membranes (0.1 mg of protein) with 5 &ml #327 anti-Src 
[23] (kindly donated by J.S. Brugge, Philadelphia, PA). Incubations 
with non-relevant mouse immunoglobulins (Sigma) were performed as 
negative controls. 
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2.5. Immunoblotting 
Polyclonal rabbit anti&c cst.1 antibodies were kindly donated by 
S.A. Courtneidge (Heidelberg, Germany) and have been described else- 
where [24]. Monoclonal mouse antibodies to phosphotyrosine (PY-20) 
were from ICN (Cleveland, OH), and rabbit polyclonal anti-EGF re- 
ceptor antibodies directed against amino acids 984996 of the human 
EGF receptor were kindly donated by L.H. Delize (Utrecht, The 
Netherlands). Immunoprecipitates were washed three times with radio- 
immunoprecipitation assay (RIPA) buffer and subjected to SDS-PAGE 
and immunoblotting [22]. Reacting antibodies were visualized by im- 
muno-gold silver staining [25]. 
2.6. Immune complex kinase assay 
Src immunoprecipitates were washed three times with RIPA buffer, 
once with HNEN buffer (50 mM HEPES, pH 75,140 mM NaCl, 5 mM 
EDTA, 1% Nonidet P-40), twice with HNE buffer (HNEN without 
Nonidet P-40) and once with phosphorylation buffer (20 mM HEPES, 
pH 7.5, and 5 mM MgCl,). Src autophosphorylation and phosphoryla- 
tion of acid-denatured rabbit muscle enolase (Boehringer-Mannheim, 
Germany), prepared according to Cooper et al. [26], was carried out in 
20 ~1 phosphorylation buffer supplemented with 3 mM MnCl, and 2 pg 
enolase. The reaction was started by the addition of 50 pM r2P]ATP 
(New England Nuclear, Berkely, CA, 3.33 Ci/mmol). After 5 min at 
30°C, 25 @,2 x concentrated sample buffer was added and the samples 
were heated at 95°C. Proteins were separated by reducing 8% SDS- 
PAGE and electroblotted to a polyvinylidene difluoride filter. Marker 
proteins were visualized by staining with Coomassie blue. Src protein 
was detected by immunoblotting as described above with cst.1 or #327 
anti-Src. Phosphate incorporation was analysed in a PhosphorImager 
coupled to ImageQuant software (Molecular Dynamics, Sunnyvale, 
CA). Alternatively, “P-labeled ATP was used in the kinase assay and 
Src protein on the filters was subsequently visualised with ?-labeled 
protein A. The application of these isotopes allows precise imaging of 
both the kinase activity and the amount of Src protein on the same 
filter. 
3. Results and discussion 
The relative expression of functional EGF receptors in 
ZR9Bll and ZRl 1 cells was determined by stimulating growth 
factor-deprived cells with EGF for 10 min, scraping off the cells 
and analyzing the amount of EGF-R and its phosphorylation 
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Fig. 1. Expression and autophosphorylation of the EGF-R. ZRl 1 cells 
and ZR9Bll cells were growth factor-deprived for 48 h, and stimulated 
with 0,5 or 50 ng/ml EGF for 10 min. Immunoblots of whole cell lysates 
were probed with either anti-EGF-R antibodies (a) or anti-phosphoty- 
rosine antibodies (b). Antibodies were visualized by immuno-gold silver 
staining [25]. 
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Fig. 2. Proliferation of ZRll and ZR9Bll cells. ZRll cells and 
ZR9Bll cells were deprived of serum for 48 h and stimulated with 
various concentrations of EGF for another 48 h. The increase in cell 
count with respect o non-stimulated cells is given. 
by immunoblotting with anti-EGF-R and anti-phosphoty- 
rosine. In accordance with the results of Valverius et al. [ 161 we 
found that in the ZRl 1 cells, an approximately 60-fold larger 
amount of EGF-R was present compared to the ZR9Bll cell 
line (Fig. la). When the parallel immunoblots were treated with 
anti-phosphotyrosine, essentially the same increase in auto- 
phosphorylation could be detected (Fig. lb). 
To determine if there was a difference in growth rate between 
the two cell lines after stimulation with EGF, we plated the cells 
at a low density, deprived them of growth factors for 48 h, and 
then stimulated the cells with EGF for another 48 h. The cells 
were counted by Methylene blue staining. Fig. 2 shows that in 
the presence of increasing concentrations of EGF, the ZRll 
cells grow much faster than the ZR9Bll cells, which are hardly 
responsive to EGF. In the absence of EGF the cells remained 
growth-suppressed. Thus, also in growth assays, the difference 
between the ZRl 1 and ZR9Bll cell lines was apparent. 
To ensure that c&c kinase was present in the cell lines, we 
performed immunoprecipitations with anti&c #327. The pre- 
cipitates were subjected to electrophoresis and transferred to 
PVDF filters, which were probed with anti-Src cst.1. In both 
cell lines, a prominent band at a molecular weight of 60,000 Da 
can be seen, both in the cytosol and in the membrane fraction 
(Fig. 3) showing that there was considerable expression of the 
Src kinase in these cell lines. The amount of c-Src present in 
both cell lines was approximately the same. A relatively large 
amount of c-Src, about 50%, was recovered in the cytosol. This 
was not due to our extraction procedure, as in other cell types 
we found most of the c-Src to be attached to membranes. 
To study whether there was a functional interaction between 
the EGF-R and the Src kinase, we performed short-term stim- 
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3. Presence of Src in ZRll and ZR9Bll cells. Cytosolic and 
membrane fractions of ZRl 1 cells and ZR9Bll cells were immunopre- 
cipitated with anti-Src antibody #327 (lanes 5-8) or non-relevant 
control antibodies (lanes 14). Precipitates were analyzed by im- 
munoblotting with anti&c cst.1 antibodies. 
ZR9Bll ZRll 
cytosol membrane cytosol membrane 
ulations with EGF, extracted cytosolic and membrane frac- 
tions, made immunoprecipitates with anti-Src #327, and, after 
extensive washing, subjected the precipitates to an immune 
complex kinase assay using acid-denatured enolase as an ex- 
ogenous substrate. A representative result is shown in Fig. 4. 
After stimulation of the cells with 100 ng/ml EGF, the activity 
of the membrane-bound Src kinase in the ZRl 1 cells was mark- 
edly increased. The specific Src activity could be calculated by 
dividing the amount of radioactivity towards enolase (deter- 
mined by quantification in the Phosphorlmager) by the amount 
of c-&c present on the immunoblot probed with cst.1, which 
was determined by densitometric scanning of the appropriate 
immunoreactive band. In the ZRll cells, which over-express 
the EGF-R, the membrane-bound specific Src kinase activity 
was found to be increased 2-fold after EGF stimulation (2.03, 
S.E.M. = 0.11, mean of three independent experiments) com- 
pared to non-stimulated cells. In the ZR9Bll cells, no such 
elevation could be found when comparing EGF-stimulated to 
non-stimulated cells (0.97-fold increase, S.E.M. = 0.21, n = 3). 
In the cytosol of both cell lines no significant increase in the 
activity towards enolase was found. 
To exclude the possibility that the activation of membrane- 
Fig. 4. Stimulation of Src kinase after EGF treatment of ZRl 1 cells. ZR9Bll and ZRl 1 cells were growth factordeprived for 48 h and treated with 
100 ng/ml EGF for 10 min (hatched bars) or left unstimulated (dotted bars). Cytosolic and membrane proteins were extracted and immunoprecipitated 
with anti-Src #327 antibodies. Immune complex kinase assays were performed and incorporation of phosphate into enolase was quantified with a 
PhosphorImager. Inset: phosphorylation of enolase by cytosolic (lanes 1 and 2) or membrane (lanes 3 and 4) anti-Src precipitates from EGF- 
stimulated (even lanes) or control cells (odd lanes), detected with a PhosphorImager. 
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Fig. 5. EGF-induced stimulation of Src kinase in other cell types. Al72 
glioblastoma cells and HER14 fibroblasts were stimulated with EGF 
(+) or left unstimulated (-) and Src was precipitated from the mem- 
brane fractions. Kinase assays were performed with [32P]ATP and after 
SDS-PAGE and transfer to PVDF filters, precipitates were twice analy- 
sed in a PhosphorImager for (a) Src protein by immunoblotting with 
anti-Src #327 and ‘ZSI-labeled protein A, and (b) tyrosine kinase activ- 
ity. Kinase activities were measured using enolase as a substrate (A172) 
or in an autokinase assay (HER14). 
bound Src by EGF was cell type restricted, we repeated the 
experiments with other EGF receptor expressing cell lines. 
Stimulation of both Al72 glioblastoma cells and HER14 
fibroblasts with EGF resulted in an increase in Src kinase 
activity in the membrane fraction (Fig. 5). Quantification of 
these data in the PhosphorImager showed a 1.8-fold (A172) and 
4.6-fold (HER14) enhancement of Src activity. 
These results show directly a functional interaction between 
the EGF-R and the Src kinase. The relationship between the 
PDGF receptor and Src has been established before. In a paper 
by Kypta et al., a physical association between Src (and also 
Yes and Fyn, two other Src family members) and the PDGF-R 
was shown after stimulation of quiescent fibroblasts with 
PDGF [ 131. In addition, the Src kinase activity was elevated 2-3 
times. The association of Fyn with the activated PDGF recep- 
tor was mediated by the SH2 domain of Fyn and resulted in 
phosphorylation of its amino-terminal part [27]. Also, the acti- 
vation of the Src family members Src, Fyn and Yes, by stimu- 
lation with CSF-I, and their association with the CSF-1 recep- 
tor has been shown recently [ 141. The amount of Src activation 
by PDGF, or CSF-1 stimulation corresponds well with the 
amount of activation we see after stimulation with EGF. 
Up to now, an interaction between the Src kinase and the 
EGF-R has been indicated only indirectly. Over-expression of 
c-Src in murine fibroblasts caused a 2- to 5-fold enhancement 
in DNA synthesis in response to EGF [28]. Kinase-defective 
Src, or Src lacking a signal for myristylation or an intact SH2 
domain, were unable to elicit this enhanced response to EGF 
in the cell lines over-expressing these mutants [29]. These find- 
ings suggest hat the presence of elevated levels of c-Src aug- 
ments normal EGF-induced signaling pathways. Another re- 
port which points to a relationship between the EGF receptor 
and the Src kinase deals with the identification of a cytoskele- 
ton-associated EGF-sensitive Src substrate, p75 [30]. Over-ex- 
pression of c-Src in murine fibroblasts leads to an increase in 
the basal tyrosine phosphorylation level of p75, yet ~75 tyrosine 
phosphorylation is further enhanced upon EGF treatment [30]. 
Recently it was shown that in human breast carcinoma cell lines 
the Src SH2 domain binds to the activated EGF-R [15]. In 
addition, endogenous Src was found to co-precipitate with ty- 
rosine-phosphorylated EGF-R [15]. These results suggest hat 
Src may become physically associated to the receptor upon 
EGF stimulation. Our data now show that EGF stimulation 
actually results in an activation of the membrane-bound Src 
tyrosine kinase. 
The fact that many oncogenes encode for tyrosine kinases 
points to a role for these enzymes in tumorigenesis. Consistent 
with this, we have shown that in all breast cancers, the protein 
tyrosine kinase (PTK) activity is enhanced compared to normal 
breast tissue, and that the increase in PTK activity may be of 
prognostic significance [22,31]. We identified the majority of 
these PTKs as the product of the c-src proto-oncogene [22]. In 
breast cancer, a prognostic role for the elevated expression of 
Neu, a growth factor receptor tyrosine kinase that is highly 
homologous to the EGF-R, has also been proposed [32-351. 
Recently it has been demonstrated that mammary tumors ex- 
pressing the neu proto-oncogene possess elevated Src kinase 
activity [36]. In addition, direct complex formation between 
Neu and Src was observed. Also the amplification or over- 
expression of the EGF receptor itself has clearly been impli- 
cated in the pathogenesis of a group of breast cancers [37-40]. 
A functional interaction between the Src kinase and the EGF 
receptor put these observations in a new perspective, as this 
may point to an important role for the two tyrosine kinases in 
the tumorigenesis of at least a subtype of breast cancers. 
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